Truist raised the firm’s price target on Tandem Diabetes (TNDM) to $27 from $24 and keeps a Hold rating on the shares. The company’s Q4 beat on incremental pharmacy channel traction and better US pump shipments were a positive, the analyst tells investors in a research note. The stock is regaining some lost ground on a potential acceleration in revenue and profit growth trajectory that the pharmacy channel pricing could engender over time, the firm adds.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNDM:
- Tandem Diabetes price target raised to $28 from $25 at Goldman Sachs
- Tandem Diabetes price target raised to $56 from $55 at Barclays
- Tandem Diabetes Care Earnings Call Signals Strategic Shift
- Midday Fly By: Supreme Court strikes down Trump tariffs
- Walmart downgraded, Etsy upgraded: Wall Street’s top analyst calls